Stages of Valvular Heart Disease Among Older Adults in the Community: The Atherosclerosis Risk in Communities Study.
aged
cohort studies
echocardiography
guidelines as topic
heart valve diseases
Journal
Circulation
ISSN: 1524-4539
Titre abrégé: Circulation
Pays: United States
ID NLM: 0147763
Informations de publication
Date de publication:
21 02 2023
21 02 2023
Historique:
pubmed:
17
12
2022
medline:
25
2
2023
entrez:
16
12
2022
Statut:
ppublish
Résumé
Limited data exist on American College of Cardiology/American Heart Association valvular heart disease (VHD) stage prevalence, progression, and association with incident cardiovascular diseases in late life. Participants in the ARIC study (Atherosclerosis Risk in Communities), a prospective community-based cohort study, underwent protocol echocardiography at ARIC visits 5 (2011-2013) and 7 (2018-2019), and their aortic stenosis, aortic regurgitation, mitral stenosis, and mitral regurgitation stage were defined according to American College of Cardiology/American Heart Association guidelines. The overall VHD stage prevalence at visit 5 was measured. The associations between VHD stages and incident adjudicated death, heart failure, coronary heart disease, stroke, and atrial fibrillation were assessed with Cox proportional hazard models adjusted for age, sex, race, hypertension, diabetes, prior myocardial infarction, heart failure, body mass index, study center, systolic blood pressure, estimated glomerular filtration rate, and low-density lipoprotein at visit 5. Longitudinal changes in VHD stage prevalence over ≈6 years were estimated with inverse probability of attrition weights to account for participant attrition. Among 6118 ARIC participants, the mean±SD age was 76±5 years, 42% were male, and 22% reported Black race. Stage A VHD was present in 39%, stage B in 17%, and stage C/D in 1.1%;, 0.7% had previously undergone valve replacement or repair. A graded association was observed between stage A, B, and C/D VHD and risk of all-cause mortality, incident heart failure, incident atrial fibrillation, and incident coronary heart disease, but not incident stroke. Similar findings were observed for stages of each valvular lesion individually. During the 6.6 years (interquartile range, 6.1-7.0 years) between visits 5 and 7 (mean age, 81±4 years), the prevalence of freedom from VHD stage decreased from 43% to 24%, whereas the prevalence of stage C/D VHD increased from 1% to 7%. Subclinical VHD is common in older adults, with 39% at risk (stage A) and 17% with progressive VHD (stage B), and is independently associated with risk of incident cardiovascular events. VHD stages progress over 6 years in late life, with a several-fold increase in prevalence of severe VHD (stage C/D), highlighting the public health importance of interventions to mitigate VHD progression.
Sections du résumé
BACKGROUND
Limited data exist on American College of Cardiology/American Heart Association valvular heart disease (VHD) stage prevalence, progression, and association with incident cardiovascular diseases in late life.
METHODS
Participants in the ARIC study (Atherosclerosis Risk in Communities), a prospective community-based cohort study, underwent protocol echocardiography at ARIC visits 5 (2011-2013) and 7 (2018-2019), and their aortic stenosis, aortic regurgitation, mitral stenosis, and mitral regurgitation stage were defined according to American College of Cardiology/American Heart Association guidelines. The overall VHD stage prevalence at visit 5 was measured. The associations between VHD stages and incident adjudicated death, heart failure, coronary heart disease, stroke, and atrial fibrillation were assessed with Cox proportional hazard models adjusted for age, sex, race, hypertension, diabetes, prior myocardial infarction, heart failure, body mass index, study center, systolic blood pressure, estimated glomerular filtration rate, and low-density lipoprotein at visit 5. Longitudinal changes in VHD stage prevalence over ≈6 years were estimated with inverse probability of attrition weights to account for participant attrition.
RESULTS
Among 6118 ARIC participants, the mean±SD age was 76±5 years, 42% were male, and 22% reported Black race. Stage A VHD was present in 39%, stage B in 17%, and stage C/D in 1.1%;, 0.7% had previously undergone valve replacement or repair. A graded association was observed between stage A, B, and C/D VHD and risk of all-cause mortality, incident heart failure, incident atrial fibrillation, and incident coronary heart disease, but not incident stroke. Similar findings were observed for stages of each valvular lesion individually. During the 6.6 years (interquartile range, 6.1-7.0 years) between visits 5 and 7 (mean age, 81±4 years), the prevalence of freedom from VHD stage decreased from 43% to 24%, whereas the prevalence of stage C/D VHD increased from 1% to 7%.
CONCLUSIONS
Subclinical VHD is common in older adults, with 39% at risk (stage A) and 17% with progressive VHD (stage B), and is independently associated with risk of incident cardiovascular events. VHD stages progress over 6 years in late life, with a several-fold increase in prevalence of severe VHD (stage C/D), highlighting the public health importance of interventions to mitigate VHD progression.
Identifiants
pubmed: 36524478
doi: 10.1161/CIRCULATIONAHA.122.061396
pmc: PMC9974863
mid: NIHMS1854135
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
638-649Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL135008
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201700002C
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL150342
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL148218
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201700004C
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201700001I
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL143224
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201700004I
Pays : United States
Organisme : NHLBI NIH HHS
ID : K24 HL152008
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201700005C
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201700001C
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201700003C
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201700002I
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201700005I
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201700003I
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL160025
Pays : United States
Références
Am J Epidemiol. 1989 Apr;129(4):687-702
pubmed: 2646917
Am J Epidemiol. 2014 Apr 15;179(8):956-66
pubmed: 24627572
Stroke. 1999 Apr;30(4):736-43
pubmed: 10187871
Circulation. 2019 Oct;140(14):1156-1169
pubmed: 31510787
J Am Soc Echocardiogr. 2003 Jul;16(7):777-802
pubmed: 12835667
J Gerontol A Biol Sci Med Sci. 2017 Mar 1;72(3):382-388
pubmed: 27470301
Am J Cardiol. 2008 Apr 1;101(7):1016-22
pubmed: 18359324
Am J Cardiol. 2001 Feb 1;87(3):298-304
pubmed: 11165964
J Am Soc Echocardiogr. 2017 Apr;30(4):372-392
pubmed: 28385280
J Am Soc Echocardiogr. 2017 Apr;30(4):303-371
pubmed: 28314623
J Am Heart Assoc. 2020 Dec;9(23):e017588
pubmed: 33222585
Circulation. 2017 Jan 17;135(3):224-240
pubmed: 27881564
J Ultrasound Med. 2018 Sep;37(9):2171-2180
pubmed: 29451314
J Am Heart Assoc. 2018 Feb 3;7(3):
pubmed: 29431107
Circulation. 2021 Feb 2;143(5):e72-e227
pubmed: 33332150
Eur Heart J. 2016 Dec 14;37(47):3515-3522
pubmed: 27354049
Heart. 2017 Nov;103(21):1696-1703
pubmed: 28432156
Eur Heart J. 2003 Jul;24(13):1231-43
pubmed: 12831818
Epidemiology. 2012 Jan;23(1):119-28
pubmed: 21989136
J Am Coll Cardiol. 2015 Oct 27;66(17):1934-41
pubmed: 26493666
Stroke. 1981 Mar-Apr;12(2 Pt 2 Suppl 1):I1-91
pubmed: 7222163
J Am Coll Cardiol. 1999 Oct;34(4):1137-44
pubmed: 10520803
J Thorac Dis. 2017 Jan;9(1):E97-E98
pubmed: 28203448
Heart. 2022 May 12;108(11):875-881
pubmed: 34433635
Am J Cardiol. 1999 Mar 15;83(6):897-902
pubmed: 10190406
Arch Intern Med. 2002 Nov 11;162(20):2345-7
pubmed: 12418948
J Am Coll Cardiol. 2000 Aug;36(2):461-7
pubmed: 10933358
J Am Coll Cardiol. 2014 Jun 10;63(22):2438-88
pubmed: 24603192
Circulation. 2020 May 26;141(21):1670-1680
pubmed: 32223336
J Am Soc Echocardiogr. 2016 May;29(5):461-9
pubmed: 26936152
Echo Res Pract. 2021 Apr 28;8(1):G19-G59
pubmed: 33709955
N Engl J Med. 1999 Jul 15;341(3):142-7
pubmed: 10403851
Circ Heart Fail. 2012 Mar 1;5(2):152-9
pubmed: 22271752
Am Heart J. 1989 Mar;117(3):636-42
pubmed: 2784023
JAMA Cardiol. 2019 Oct 1;4(10):997-1006
pubmed: 31483438
Eur Heart J. 2004 Feb;25(3):199-205
pubmed: 14972419
J Clin Epidemiol. 1996 Feb;49(2):223-33
pubmed: 8606324
JAMA Cardiol. 2018 Nov 1;3(11):1060-1068
pubmed: 30285058
Am Heart J. 2018 Sep;203:39-48
pubmed: 30015067
N Engl J Med. 2005 Mar 3;352(9):875-83
pubmed: 15745978
Circulation. 2001 Dec 11;104(24):2996-3007
pubmed: 11739319
Lancet. 2006 Sep 16;368(9540):1005-11
pubmed: 16980116
Circ Arrhythm Electrophysiol. 2019 Oct;12(10):e007390
pubmed: 31607148
Eur Heart J. 2017 Apr 21;38(16):1194-1203
pubmed: 28039339
J Am Coll Cardiol. 1993 Apr;21(5):1220-5
pubmed: 8459080
Heart. 2005 Nov;91(11):1389-93
pubmed: 15797932
Am Heart J. 2009 Jul;158(1):111-7
pubmed: 19540400
Circ Cardiovasc Imaging. 2014 Jan;7(1):173-81
pubmed: 24214885
Am J Kidney Dis. 2013 Oct;62(4):691-702
pubmed: 23769137